Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 15, Issue 7, Pages 399-400Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41571-018-0030-2
Keywords
-
Categories
Ask authors/readers for more resources
Drug regulators' acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available